BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21051912)

  • 1. Trimodal therapy for inflammatory breast cancer: a surgeon's perspective.
    Li BD; Sicard MA; Ampil F; Abreo F; Lilien D; Chu QD; Burton GV
    Oncology; 2010; 79(1-2):3-12. PubMed ID: 21051912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options.
    Gentilini O; Masullo M; Rotmensz N; Peccatori F; Mazzarol G; Smeets A; Simsek S; De Dosso S; Veronesi P; Intra M; Zurrida S; Viale G; Goldhirsch A; Veronesi U
    Eur J Surg Oncol; 2005 Apr; 31(3):232-6. PubMed ID: 15780556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons learned from an unusual case of inflammatory breast cancer.
    Harrison AM; Zendejas B; Ali SM; Scow JS; Farley DR
    J Surg Educ; 2012; 69(3):350-4. PubMed ID: 22483137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidating an uncommon disease: inflammatory breast cancer.
    Crane K
    J Natl Cancer Inst; 2011 Sep; 103(18):1358-60. PubMed ID: 21881039
    [No Abstract]   [Full Text] [Related]  

  • 6. Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment.
    Silverstein MJ; Recht A; Lagios MD; Bleiweiss IJ; Blumencranz PW; Gizienski T; Harms SE; Harness J; Jackman RJ; Klimberg VS; Kuske R; Levine GM; Linver MN; Rafferty EA; Rugo H; Schilling K; Tripathy D; Vicini FA; Whitworth PW; Willey SC
    J Am Coll Surg; 2009 Oct; 209(4):504-20. PubMed ID: 19801324
    [No Abstract]   [Full Text] [Related]  

  • 7. Inflammatory breast cancer: early recognition and diagnosis is critical.
    Hester RH; Hortobagyi GN; Lim B
    Am J Obstet Gynecol; 2021 Oct; 225(4):392-396. PubMed ID: 33845027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
    Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
    Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer in very young women.
    Liukkonen S; Leidenius M; Saarto T; Sjöström-Mattson J
    Eur J Surg Oncol; 2011 Dec; 37(12):1030-7. PubMed ID: 21937191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Male breast cancer: a survey at the Helsinki University Central Hospital during 1981-2006.
    Liukkonen S; Saarto T; Mäenpää H; Sjöström-Mattson J
    Acta Oncol; 2010 Apr; 49(3):322-7. PubMed ID: 20397767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of and therapeutic options for contralateral axillary lymph node metastasis in breast cancer.
    Morcos B; Jaradat I; El-Ghanem M
    Eur J Surg Oncol; 2011 May; 37(5):418-21. PubMed ID: 21316187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: single-center experiences.
    Oven Ustaalioglu BB; Bilici A; Kefeli U; Seker M; Yildirim E; Salepci T; Oncel M; Kement M; Gumus M
    Oncology; 2010; 79(1-2):105-11. PubMed ID: 21088436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin thickening as unique pathologic sign of an inflammatory breast cancer: a case report and review of the literature.
    Ballesio L; D'Ambrosio I; Ravazzolo N; Angeletti M; Di Pastena F; Tardioli S; Lodise P; Marini M
    Clin Ter; 2011; 162(4):351-4. PubMed ID: 21912823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is breast conservation therapy superior to mastectomy for women with triple-negative breast cancers?
    Pignol JP; Rakovitch E; Olivotto IA
    J Clin Oncol; 2011 Jul; 29(21):2841-3. PubMed ID: 21670459
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.
    Hieken TJ; Murphy BL; Boughey JC; Degnim AC; Glazebrook KN; Hoskin TL
    Clin Breast Cancer; 2018 Aug; 18(4):e501-e506. PubMed ID: 29089281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
    Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
    Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pathologic diagnosis and histopathology record of breast cancer].
    Cserni G; Francz M; Járay B; Kálmán E; Kovács I; Kulka J; Orosz Z; Udvarhelyi N; Vass L
    Magy Onkol; 2010 Sep; 54(3):217-26. PubMed ID: 20870599
    [No Abstract]   [Full Text] [Related]  

  • 19. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy.
    Tsai CJ; Li J; Gonzalez-Angulo AM; Allen PK; Woodward WA; Ueno NT; Lucci A; Krishnamurthy S; Gong Y; Yang W; Cristofanilli M; Valero V; Buchholz TA
    Am J Clin Oncol; 2015 Jun; 38(3):242-7. PubMed ID: 23648437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.